Treatment response and residual-disease monitoring in initial and relapsed TEL-AML1 positive childhood ALL.
Seeger
K
K
Dept of Pediatric Oncology/Hematology, Charité Medical Center, Berlin, Germany.
Viehmann
S
S
Buchwald
D
D
Harbott
J
J
Schrappe
M
M
Stary
J
J
Henze
G
G
Trka
J
J
D050676:Core Binding Factor Alpha 2 Subunit; D049711:History, Modern 1601-; D006801:Humans; D016130:Immunophenotyping; D008991:Monitoring, Physiologic; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D012008:Recurrence; D016896:Treatment Outcome; D000097764:ETS Translocation Variant 6 Protein
D050676:Core Binding Factor Alpha 2 Subunit; D015514:Oncogene Proteins, Fusion; C102421:TEL-AML1 fusion protein; D000097764:ETS Translocation Variant 6 Protein